Corbus Pharmaceuticals Holdings, Inc. CRBP

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001595097

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $168.2M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, short runway, thin data, dege...
Inputs computable	6 of 14
Graded from	filings received through Mar 9, 2026 243 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$3.07 2026-11-06; market equity $59.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

All references in this report to "Corbus," the "Company," "we," "us," or "our" mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 45.3						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(8.7%)	(6.6%)	45.3	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 48.6					
Twelve-month failure probability	0.68%	0.08%	82.3	249	2026-06-30
Altman Z double-prime	(0.98)	(0.37)	41.2	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	8.07x	2.94x	22.2	828	2025-12-31
Growth and financing, sleeve percentile 43.6					
Revenue growth, three-year compound	not computable	10.0%			
current value must be positive and the base must exceed $100,000					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 11					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	36.4%	2.2%	12.8	696	2025-12-31
Net share issuance, one year	45.0%	2.5%	74.4	630	2026-03-06

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 45.0%
Short runway	cash runway is 3.2 months
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(43.9%)	(2.1%)	19
Distance from 52-week high	(74.7%)	(30.5%)	12
EBIT to enterprise value	(158.3%)	(1.5%)	5
Free cash flow yield	(108.6%)	(1.0%)	6
Book value to price	1.72	0.29	94
Sales to price	0.00	0.30	0
Composite equity issuance, five years	153.6%	21.4%	85
Relative strength against the sector, log excess return	(0.75)	(0.19)	19

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$23.4M
Operating cash flow, four quarters	-$86.7M
Months of runway	3.2
Days since last periodic filing	93 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$5.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$78.5M	2025-12-31	2026-03-09	10-K	26-098530
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$64.5M	2025-12-31	2026-03-09	10-K	26-098530
3	assets	us-gaap:Assets	$168.2M	2025-12-31	2026-03-09	10-K	26-098530
4	assets	us-gaap:Assets	$155.9M	2024-12-31	2026-03-09	10-K	26-098530
5	current assets	us-gaap:AssetsCurrent	$167.0M	2025-12-31	2026-03-09	10-K	26-098530
6	current liabilities	us-gaap:LiabilitiesCurrent	$20.7M	2025-12-31	2026-03-09	10-K	26-098530
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$555.4M	2025-12-31	2026-03-09	10-K	26-098530
8	operating income	us-gaap:OperatingIncomeLoss	-$85.3M	2025-12-31	2026-03-09	10-K	26-098530
9	book equity	us-gaap:StockholdersEquity	$147.5M	2025-12-31	2026-03-09	10-K	26-098530
10	liabilities	us-gaap:Liabilities	$20.7M	2025-12-31	2026-03-09	10-K	26-098530
11	total debt	us-gaap:LongTermDebt	$17.9M	2023-12-31	2024-03-12	10-K	24-030133
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$13.7M	2023-12-31	2025-03-11	10-K	25-037335
13	operating income	us-gaap:OperatingIncomeLoss	-$45.1M	2023-12-31	2025-03-11	10-K	25-037335
14	depreciation amortization	us-gaap:Depreciation	$600,000	2023-12-31	2025-03-11	10-K	25-037335
15	operating income	us-gaap:OperatingIncomeLoss	-$8.9M	2015-12-31	2018-03-12	10-K	18-003208
16	interest expense	us-gaap:InterestExpense	$2,440	2015-12-31	2016-03-28	10-K	16-015403
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2022-12-31	2023-03-07	10-K	23-006469
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$881,705	2021-12-31	2023-03-07	10-K	23-006469
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.9M	2020-12-31	2022-03-08	10-K	22-003145
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$36.1M	2019-12-31	2021-03-15	10-K	21-006016
21	assets	us-gaap:Assets	$28.3M	2023-12-31	2025-03-11	10-K	25-037335
22	assets	us-gaap:Assets	$66.3M	2022-12-31	2024-03-12	10-K	24-030133
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	17,736,464	2026-03-06	2026-03-09	10-K	26-098530
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,232,228	2025-03-07	2025-03-11	10-K	25-037335

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.